Citigroup Inc. Reduces Stake in AnaptysBio, Inc.

Biotechnology company's shares see volatility amid analyst rating changes and estimate revisions

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Citigroup Inc. has significantly reduced its position in AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on developing therapeutic antibody products. According to a recent SEC filing, Citigroup cut its stake in AnaptysBio by 93.3% during the third quarter, selling nearly 976,000 shares.

Why it matters

The reduction in Citigroup's holding in AnaptysBio reflects broader volatility and uncertainty around the biotechnology company's stock. Analysts have issued a mix of rating changes and estimate revisions, with some positive sentiment around the company's progress, but also concerns about near-term profitability. This highlights the challenges facing smaller biotech firms as they navigate the drug development process.

The details

Citigroup previously owned 0.25% of AnaptysBio, but has now trimmed its position to just 70,534 shares. The move comes as AnaptysBio's stock has seen significant fluctuations, hitting a 52-week high of $63.47 in recent months but also dipping as low as $15.32 over the past year. Analysts have a range of views, with Stifel Nicolaus raising its price target to $85 while maintaining a buy rating, even as HC Wainwright issued a mixed set of estimate changes that included lowering near-term profitability forecasts.

  • Citigroup reduced its AnaptysBio stake during the 3rd quarter of 2026.

The players

Citigroup Inc.

A major global financial services company that has significantly reduced its ownership stake in biotechnology firm AnaptysBio, Inc.

AnaptysBio, Inc.

A clinical-stage biotechnology company focused on developing therapeutic antibody products, whose stock has seen volatility amid analyst rating changes and estimate revisions.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The reduction in Citigroup's AnaptysBio stake underscores the challenges facing smaller biotech firms as they navigate the drug development process. Analysts have issued a mix of views, highlighting the volatility and uncertainty surrounding AnaptysBio's stock performance.